Clinical trial
Far Eastern Memorial Hospital
Name
111207-F
Description
The aim of this study is to evaluate the efficacy between dienogest and danazol.
Trial arms
Trial start
2023-02-25
Estimated PCD
2025-12-31
Trial end
2025-12-31
Status
Recruiting
Phase
Early phase I
Treatment
Dienogest
Dienogest 2 mg per day
Arms:
Dienogest
Danazol
Danzol 200MG per day
Arms:
Danazol
Size
120
Primary endpoint
The change of severity in dysmenorrhea
16 weeks
Eligibility criteria
Inclusion Criteria:
* \> 20 years old
* Have an endometriosis-related condition (including adenomyosis, adenomyoma, ovarian endometrioma, or pelvic endometriosis).
Exclusion Criteria:
* Minors.
* Have a history of breast cancer or other cancers.
* Patients with vascular obstruction such as stroke.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 120, 'type': 'ESTIMATED'}}
Updated at
2023-03-29
1 organization
2 products
1 indication
Organization
Far Eastern Memorial HospitalProduct
DienogestIndication
EndometriosisProduct
Danazol